Living Cell Technologies closes IPO
Friday, 27 August, 2004
Living Cell Technologies has closed its IPO after raising AUD$6.36 million from institutional and retail clients of underwriting stockbroker Taylor Collinson.
The company is expected to move from the Newcastle stock exchange (NSX) to the ASX on September 1, and has been suspended from trading on the NSX in preparation.
"LCT is a unique biotechnology company with an international infrastructure, significant scientific and commercial potential and a clear path to market. Transferring to the ASX is a significant and strategic step in our development and the keen interest in our capital raising not only validates our hard work to date but will underscore continued success in further developing our unique technology," said CEO David Collinson in a statement.
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
